TM38837

CAS No. 1253641-65-4

TM38837( —— )

Catalog No. M22051 CAS No. 1253641-65-4

TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 113 In Stock
10MG 149 In Stock
25MG 258 In Stock
50MG 405 In Stock
100MG 597 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TM38837
  • Note
    Research use only, not for human use.
  • Brief Description
    TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.
  • Description
    TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes. TM38837, a novel, largely peripherally restricted CB1 antagonist, in terms of fear-promoting consequences of systemic vs. intracerebral injections. Different groups of male C57BL/6 N mice underwent auditory fear conditioning, followed by re-exposure to the tone. Mice were treated per os (p.o.) with TM38837 (10, 30, or 100 mg/kg), rimonabant (10 mg/kg; a brain penetrating CB1 antagonist/inverse agonist which served as a positive control), or vehicle, 2 h prior the tone presentation. Only the high dose of TM38837 (100 mg/kg) induced a significant increase in freezing behavior, similar to that induced by rimonabant (10 mg/kg) (p < 0.001). If injected into the brain both TM38837 (10 or 30 μg/mouse) and rimonabant (1 or 10 μg/mouse) caused a sustained fear response to the tone, which was more pronounced after rimonabant treatment. Taken together, TM38837 was at least one order of magnitude less effective in promoting fear responses than rimonabant. Given the equipotency of the two CB1 antagonists with regard to weight loss and metabolic syndrome-like symptoms in rodent obesity models, our results point to a critical dose range in which TM3887 might be beneficial for indications such as obesity and metabolic disorders with limited risk of fear-promoting effects.
  • In Vitro
    ——
  • In Vivo
    CB1 antagonist 4 (compound 8) (10-100 mg/kg; p.o.) induces a significant increase in freezing behavior at 100 mg/kg. Animal Model:7-8 weeks old male C57BL/6 N mice (B6N) Dosage:10, 30, or 100 mg/kg Administration:p.o.Result:High dose (100 mg/kg) induced a significant increase in freezing behavior.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    CB1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1253641-65-4
  • Formula Weight
    617.51
  • Molecular Formula
    C30H25Cl2F3N4OS
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:40 mg/mL (64.77 mM; Need ultrasonic)
  • SMILES
    CCC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(S1)C#CC1=CC=C(C=C1)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Micale V, et al. The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows ReducedFear-Promoting Effects in Mice. Front Pharmacol. 2019 Mar 20;10:207.
molnova catalog
related products
  • AM-630

    A potent and selective inverse agonist for the cannabinoid receptor CB2 with Ki of 32.1 nM, 165-fold selectivity over CB1.

  • MK-9470

    MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM.

  • N-Oleoyl glycine

    N-Oleoyl glycine, a lipoamino acid, was able to promote 3T3-L1 adipogenesis through the activation of CB1 receptor and the enhancement of insulin-mediated Akt signaling pathway.